Prometheus secures $12 billion to develop artificial general engineers as biotech deals surge
read at STAT ↗DealPositive
Prometheus announced a $12 billion capital raise aimed at building what it calls “artificial general engineers,” a new class of AI tools for biopharma research and development.
Nonprofit Blood Cancer United acquired a shelved pediatric leukemia drug and said it will distribute the therapy at no cost to patients.
Eli Lilly and Nvidia each invested in Abridge, a platform that uses artificial intelligence to streamline clinical trial recruitment and other study processes.
source
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: Prometheus raises $12 billion in capital for artificial engineers”
read at STAT ↗374 words · retrieved Jun 12
comments(0)
5-min edit window · permanent after that